A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 (Mitiperstat) in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis
Latest Information Update: 12 Apr 2024
At a glance
- Drugs Mitiperstat (Primary)
- Indications Fibrosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms COSMOS
- Sponsors AstraZeneca
Most Recent Events
- 09 Apr 2024 Status changed from active, no longer recruiting to completed.
- 28 Dec 2023 Planned End Date changed from 1 Jul 2024 to 25 Mar 2024.
- 28 Dec 2023 Planned primary completion date changed from 1 Jul 2024 to 25 Mar 2024.